Cord blood transplants supported by unrelated donor CD34+ progenitor cells
暂无分享,去创建一个
M. Cushing | U. Gergis | N. Orfali | Yen-Michael S. Hsu | T. Shore | S. Mayer | Danielle Guarneri | A. Phillips | K. van Besien | J. Hsu | A. Mokhtar | Alexandra Gomez-Arteaga | S. Chase
[1] U. Gergis,et al. Seven Years of Haplo-Cord Transplantation: Immune Reconstitution and Outcomes Using Anti-Thymocyte Globulin , 2020 .
[2] S. Montoto,et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. , 2019, The Lancet. Haematology.
[3] W. Stock,et al. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. , 2019, Blood advances.
[4] H. Carraway,et al. When should transplant physicians think about familial blood cancers? , 2019, Journal of Clinical Haematology.
[5] K. van Besien,et al. Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] M. Labopin,et al. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation , 2018, American journal of hematology.
[7] I. Buño,et al. Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. , 2017, Blood advances.
[8] K. Besien,et al. Against the odds: haplo-cord grafts protect from GvHD and relapse , 2017, Bone Marrow Transplantation.
[9] M. Perales,et al. Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] J. Wagner,et al. Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] H. Rennert,et al. Haplo-cord transplant: HLA-matching determines graft dominance , 2017, Leukemia & lymphoma.
[12] J. Kurtzberg,et al. Excellent Outcomes in 1589 Patients Receiving Umbilical Cord Blood Transplantation Using Unlicensed Units From a Centralized Cord Blood Registry , 2017 .
[13] J. Sierra,et al. Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] H. Rennert,et al. Cord blood chimerism and relapse after haplo-cord transplantation , 2017, Leukemia & lymphoma.
[15] F. Appelbaum,et al. Cord-Blood Transplantation in Patients with Minimal Residual Disease. , 2016, The New England journal of medicine.
[16] D. Pollyea,et al. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation , 2016, Bone Marrow Transplantation.
[17] R. Larson,et al. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] R. Larson,et al. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival , 2016, Haematologica.
[19] B. Wood,et al. Cord-Blood Transplantation in Patients with Minimal Residual Disease. , 2016, The New England journal of medicine.
[20] J. Sierra,et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia , 2015, Leukemia.
[21] M. MacMillan,et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. , 2015, Blood.
[22] S. Devine,et al. Results of a prospective multicentre myeloablative double‐unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia , 2015, British journal of haematology.
[23] I. Buño,et al. Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] I. Buño,et al. Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells , 2014, Bone Marrow Transplantation.
[25] A. Zachary,et al. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[26] R. Larson,et al. Immune reconstitution after combined haploidentical and umbilical cord blood transplant , 2013, Leukemia & lymphoma.
[27] J. Goldberg,et al. A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[28] R. Larson,et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. , 2011, Blood.
[29] J. Wingard,et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.
[30] I. Millán,et al. Immune reconstitution after cord blood transplants supported by coinfusion of mobilized hematopoietic stem cells from a third party donor , 2009, Bone Marrow Transplantation.
[31] E. Shpall,et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. , 2007, Blood.
[32] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .